Esther Lutgens

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3645253/publications.pdf

Version: 2024-02-01

210 papers	16,217 citations	16411 64 h-index	18075 120 g-index
214 all docs	214 docs citations	214 times ranked	20794 citing authors

#	Article	IF	Citations
1	Immunotherapy and cardiovascular diseases: novel avenues for immunotherapeutic approaches. QJM - Monthly Journal of the Association of Physicians, 2023, 116, 271-278.	0.2	5
2	Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophagesâ€™ transition into a pro-inflammatory state. Cardiovascular Research, 2023, 119, 1146-1160.	1.8	18
3	Apolipoprotein A1 deficiency in mice primes bone marrow stem cells for T cell lymphopoiesis. Journal of Cell Science, 2022, 135, .	1.2	4
4	Structural anomalies in a published NMR-derived structure of IRAK-M. Journal of Molecular Graphics and Modelling, 2022, 111, 108061.	1.3	1
5	Stabilin-1 mediates beneficial monocyte recruitment and tolerogenic macrophage programming during CVB3-induced viral myocarditis. Journal of Molecular and Cellular Cardiology, 2022, 165, 31-39.	0.9	7
6	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2022, 118, 3016-3051.	1.8	30
7	Immuno-PET Imaging of Atherosclerotic Plaques with [89Zr]Zr-Anti-CD40 mAbâ€"Proof of Concept. Biology, 2022, 11, 408.	1.3	3
8	Low Density Lipoprotein Exposure of Plasmacytoid Dendritic Cells Blunts Toll-like Receptor 7/9 Signaling via NUR77. Biomedicines, 2022, 10, 1152.	1.4	1
9	The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease. Journal of Cardiovascular Translational Research, 2021, 14, 13-22.	1.1	34
10	Lose the helpersâ€¦ get â€˜remoteâ€™ regulators!. Cardiovascular Research, 2021, 117, 635-636.	1.8	0
11	Are we underestimating the potential for cardiotoxicity related to immune checkpoint inhibitors?. European Heart Journal, 2021, 42, 1632-1635.	1.0	18
12	Deficiency of Endothelial CD40 Induces a Stable Plaque Phenotype and Limits Inflammatory Cell Recruitment to Atherosclerotic Lesions in Mice. Thrombosis and Haemostasis, 2021, 121, 1530-1540.	1.8	14
13	Prosaposin mediates inflammation in atherosclerosis. Science Translational Medicine, 2021, 13, .	5.8	42
14	SPARCing the clot. Blood, 2021, 137, 1441-1442.	0.6	2
15	Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem. , 2021, 9, e002916.		29
16	Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease. Nature Communications, 2021, 12, 3754.	5.8	39
17	Glucocorticoid induced TNF receptor family-related protein (GITR) â€“ A novel driver of atherosclerosis. Vascular Pharmacology, 2021, 139, 106884.	1.0	3
18	Soluble CD40 Levels in Plasma Are Associated with Cardiovascular Disease and in Carotid Plaques with a Vulnerable Phenotype. Journal of Stroke, 2021, 23, 367-376.	1.4	9

#	Article	IF	Citations
19	Targeting cytokines and immune checkpoints in atherosclerosis with monoclonal antibodies. Atherosclerosis, 2021, 335, 98-109.	0.4	8
20	Diverse ultrastructural landscape of atherosclerotic endothelium. Atherosclerosis, 2021, 339, 35-45.	0.4	8
21	Disruption of circadian rhythm by alternating lightâ€dark cycles aggravates atherosclerosis development in APOE*3â€Leiden.CETP mice. Journal of Pineal Research, 2020, 68, e12614.	3.4	45
22	rs1883832: a CD40 single-nucleotide polymorphism for predicting coronary heart disease in humans. Cardiovascular Research, 2020, 116, 1095-1096.	1.8	4
23	Deletion of haematopoietic Dectin-2 or CARD9 does not protect from atherosclerosis development under hyperglycaemic conditions. Diabetes and Vascular Disease Research, 2020, 17, 147916411989214.	0.9	6
24	Microanatomy of the Human Atherosclerotic Plaque by Single-Cell Transcriptomics. Circulation Research, 2020, 127, 1437-1455.	2.0	283
25	Autophagy unleashes noncanonical microRNA functions. Autophagy, 2020, 16, 2294-2296.	4.3	6
26	Immune Checkpoint Inhibitor Therapy Aggravates T Cellâ€“Driven Plaque Inflammation in Atherosclerosis. JACC: CardioOncology, 2020, 2, 599-610.	1.7	69
27	Regulatory T Cell Metabolism in Atherosclerosis. Metabolites, 2020, 10, 279.	1.3	12
28	CD40/CD40L and Related Signaling Pathways in Cardiovascular Health and Diseaseâ€”The Pros and Cons for Cardioprotection. International Journal of Molecular Sciences, 2020, 21, 8533.	1.8	28
29	Inhibition of PFKFB3 Hampers the Progression of Atherosclerosis and Promotes Plaque Stability. Frontiers in Cell and Developmental Biology, 2020, 8, 581641.	1.8	29
30	Glucocorticoid-induced tumour necrosis factor receptor family-related protein (GITR) drives atherosclerosis in mice and is associated with an unstable plaque phenotype and cerebrovascular events in humans. European Heart Journal, 2020, 41, 2938-2948.	1.0	22
31	Antibody-Mediated Inhibition of CTLA4 Aggravates Atherosclerotic Plaque Inflammation and Progression in Hyperlipidemic Mice. Cells, 2020, 9, 1987.	1.8	43
32	Macrophage ATP citrate lyase deficiency stabilizes atherosclerotic plaques. Nature Communications, 2020, 11, 6296.	5.8	70
33	Short-term regulation of hematopoiesis by lipoprotein(a) results in the production of pro-inflammatory monocytes. International Journal of Cardiology, 2020, 315, 81-85.	0.8	13
34	Noncanonical inhibition of caspase-3 by a nuclear microRNA confers endothelial protection by autophagy in atherosclerosis. Science Translational Medicine, 2020, 12, .	5.8	88
35	E3 Ubiquitin Ligases as Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease. Frontiers in Cardiovascular Medicine, 2020, 7, 106.	1.1	5
36	Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease. , 2020, 8, e000300.		42

#	Article	IF	Citations
37	Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. American Journal of Clinical Nutrition, 2020, 112, 413-426.	2.2	96
38	Myeloid Ezh2 Deficiency Limits Atherosclerosis Development. Frontiers in Immunology, 2020, 11, 594603.	2.2	11
39	Atherosclerosis of the Carotid Artery. , 2020, , 69-91.		1
40	Modification of histone 3 lysine 27 (H3K27) trimethylation in EZH2 and JMJD3 deficient T cells attenuates atherosclerosis through polarization towards anti-inflammatory phenotypes. European Heart Journal, 2020, 41, .	1.0	0
41	Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis. , 2019, 193, 50-62.		41
42	Rational modulator design by exploitation of proteinâ€“protein complex structures. Future Medicinal Chemistry, 2019, 11, 1015-1033.	1.1	12
43	Depletion of CD40 on CD11c+ cells worsens the metabolic syndrome and ameliorates hepatic inflammation during NASH. Scientific Reports, 2019, 9, 14702.	1.6	18
44	Endothelial TGF-Î² signalling drives vascular inflammation and atherosclerosis. Nature Metabolism, 2019, 1, 912-926.	5.1	172
45	Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology. Cardiovascular Research, 2019, 115, 1385-1392.	1.8	58
46	Immunotherapy for cardiovascular disease. European Heart Journal, 2019, 40, 3937-3946.	1.0	127
47	The Link between Hematopoiesis and Atherosclerosis. New England Journal of Medicine, 2019, 380, 1869-1871.	13.9	13
48	Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death. Nature, 2019, 569, 236-240.	13.7	268
49	Germinal Centerâ€“Derived Antibodies Promote Atherosclerosis Plaque Size and Stability. Circulation, 2019, 139, 2466-2482.	1.6	51
50	Deletion of hematopoietic Dectin-2 or CARD9 does not protect against atherosclerotic plaque formation in hyperlipidemic mice. Scientific Reports, 2019, 9, 4337.	1.6	10
51	OP0221â€…OLIGOMERIC S100A4 INDUCES MONOCYTE INNATE IMMUNE MEMORY. , 2019, , .		0
52	Deficiency of T cell CD40L has minor beneficial effects on obesity-induced metabolic dysfunction. BMJ Open Diabetes Research and Care, 2019, 7, e000829.	1.2	6
53	Peritoneal macrophages have an impaired immune response in obesity which can be reversed by subsequent weight loss. BMJ Open Diabetes Research and Care, 2019, 7, e000751.	1.2	10
54	Epigenetic Quenching of VSMC Inflammation in CVD. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2199-2200.	1.1	2

#	Article	IF	Citations
55	Deficiency of the T cell regulator Casitas B-cell lymphoma-B aggravates atherosclerosis by inducing CD8+ T cell-mediated macrophage death. European Heart Journal, 2019, 40, 372-382.	1.0	37
56	Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. Cardiovascular Research, 2019, 115, 10-19.	1.8	72
57	Macrophage CD40 signaling drives experimental autoimmune encephalomyelitis. Journal of Pathology, 2019, 247, 471-480.	2.1	21
58	Small molecule-mediated inhibition of CD40-TRAF6 reduces adverse cardiac remodelling in pressure overload induced heart failure. International Journal of Cardiology, 2019, 279, 141-144.	0.8	14
59	CD40L Deficiency Protects Against Aneurysm Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1076-1085.	1.1	18
60	Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. Nature Biomedical Engineering, 2018, 2, 279-292.	11.6	94
61	Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis. Journal of the American College of Cardiology, 2018, 71, 527-542.	1.2	149
62	Exploring immune checkpoints as potential therapeutic targets in atherosclerosis. Cardiovascular Research, 2018, 114, 368-377.	1.8	64
63	CD40L controls obesity-associated vascular inflammation, oxidative stress, and endothelial dysfunction in high fat diet-treated and db/db mice. Cardiovascular Research, 2018, 114, 312-323.	1.8	37
64	Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases. European Heart Journal, 2018, 39, 3521-3527.	1.0	44
65	Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis. Current Opinion in Lipidology, 2018, 29, 381-388.	1.2	8
66	A Defective Pentose Phosphate Pathway Reduces Inflammatory Macrophage Responses during Hypercholesterolemia. Cell Reports, 2018, 25, 2044-2052.e5.	2.9	140
67	Inhibiting Inflammation with Myeloid Cell-Specific Nanobiologics Promotes Organ Transplant Acceptance. Immunity, 2018, 49, 819-828.e6.	6.6	161
68	FP526VASCULAR CXCR4 LIMITS ATHEROSCLEROSIS BY MAINTAINING ARTERIAL INTEGRITY. Nephrology Dialysis Transplantation, 2018, 33, i216-i216.	0.4	1
69	Scientists on the Spot: Esther Lutgens on the immune system and atherosclerosis. Cardiovascular Research, 2018, 114, e113-e113.	1.8	0
70	Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice. European Journal of Preventive Cardiology, 2018, 25, 948-955.	0.8	46
71	2016 Jeffrey M. Hoeg Award Lecture. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1678-1688.	1.1	12
72	Future directions for therapeutic strategies in post-ischaemic vascularization: a position paper from European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology. Cardiovascular Research, 2018, 114, 1411-1421.	1.8	19

#	Article	IF	Citations
73	Macrophage CD40 plays a minor role in obesity-induced metabolic dysfunction. PLoS ONE, 2018, 13, e0202150.	1.1	6
74	Myeloid Kdm6b deficiency results in advanced atherosclerosis. Atherosclerosis, 2018, 275, 156-165.	0.4	22
75	Commonly available hematological biomarkers are associated with the extent of coronary calcifications. Atherosclerosis, 2018, 275, 166-173.	0.4	10
76	High Fat Diet Increases Circulating Endocannabinoids Accompanied by Increased Synthesis Enzymes in Adipose Tissue. Frontiers in Physiology, 2018, 9, 1913.	1.3	40
77	Vascular CXCR4 Limits Atherosclerosis by Maintaining Arterial Integrity. Circulation, 2017, 136, 388-403.	1.6	128
78	Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation. Science Translational Medicine, 2017, 9, .	5.8	121
79	Macrophage Kdm6b controls the pro-fibrotic transcriptome signature of foam cells. Epigenomics, 2017, 9, 383-391.	1.0	24
80	Constitutive CD40 Signaling in Dendritic Cells Limits Atherosclerosis by Provoking Inflammatory Bowel Disease and Ensuing Cholesterol Malabsorption. American Journal of Pathology, 2017, 187, 2912-2919.	1.9	11
81	CD27 co-stimulation increases the abundance of regulatory T cells and reduces atherosclerosis in hyperlipidaemic mice. European Heart Journal, 2017, 38, 3590-3599.	1.0	35
82	Helminth antigens counteract a rapid high-fat diet-induced decrease in adipose tissue eosinophils. Journal of Molecular Endocrinology, 2017, 59, 245-255.	1.1	17
83	Atherosclerosis. Current Opinion in Lipidology, 2017, 28, 220-221.	1.2	2
84	Inhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation. Journal of Neuroinflammation, 2017, 14, 105.	3.1	32
85	Immune Modulation of Brown(ing) Adipose Tissue in Obesity. Endocrine Reviews, 2017, 38, 46-68.	8.9	50
86	Alterations in systemic levels of Th1, Th2, and Th17 cytokines in overweight adolescents and obese mice. Pediatric Diabetes, 2017, 18, 714-721.	1.2	10
87	Microvesicles in vascular homeostasis and diseases. Thrombosis and Haemostasis, 2017, 117, 1296-1316.	1.8	193
88	CD70 limits atherosclerosis and promotes macrophage function. Thrombosis and Haemostasis, 2017, 117, 164-175.	1.8	21
89	Inflammation, but not recruitment, of adipose tissue macrophages requires signalling through Mac-1 (CD11b/CD18) in diet-induced obesity (DIO). Thrombosis and Haemostasis, 2017, 117, 325-338.	1.8	25
90	The CD40â€“CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. Frontiers in Immunology, 2017, 8, 1791.	2.2	56

#	Article	IF	Citations
91	Novel molecular imaging ligands targeting matrix metalloproteinases 2 and 9 for imaging of unstable atherosclerotic plaques. PLoS ONE, 2017, 12, e0187767.	1.1	22
92	Unique properties of thymic antigen-presenting cells promote epigenetic imprinting of alloantigen-specific regulatory T cells. Oncotarget, 2017, 8, 35542-35557.	0.8	19
93	Atherosclerosis. Current Opinion in Lipidology, 2016, 27, 209-215.	1.2	207
94	Liposomal prednisolone promotes macrophage lipotoxicity in experimental atherosclerosis. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1463-1470.	1.7	32
95	BCG lowers plasma cholesterol levels and delays atherosclerotic lesion progression in mice. Atherosclerosis, 2016, 251, 6-14.	0.4	27
96	CD40 in coronary artery disease: a matter of macrophages?. Basic Research in Cardiology, 2016, 111, 38.	2.5	37
97	Constitutive GITR Activation Reduces Atherosclerosis by Promoting Regulatory CD4 ⁺ T-Cell Responsesâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1748-1752.	1.1	28
98	Atherosclerosis. Current Opinion in Lipidology, 2016, 27, 308-309.	1.2	0
99	Resveratrol Inhibits Aortic Root Dilatation in the Fbn1 ^{C1039G/+} Marfan Mouse Model. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1618-1626.	1.1	44
100	Dietâ€induced obesity in mice diminishes hematopoietic stem and progenitor cells in the bone marrow. FASEB Journal, 2016, 30, 1779-1788.	0.2	69
101	Platelet CD40 Exacerbates Atherosclerosis by Transcellular Activation of Endothelial Cells and Leukocytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 482-490.	1.1	90
102	Interferon-Î² promotes macrophage foam cell formation by altering both cholesterol influx and efflux mechanisms. Cytokine, 2016, 77, 220-226.	1.4	29
103	Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential. Cellular and Molecular Life Sciences, 2016, 73, 901-922.	2.4	93
104	Ablation of CD8Î±+ dendritic cell mediated cross-presentation does not impact atherosclerosis in hyperlipidemic mice. Scientific Reports, 2015, 5, 15414.	1.6	19
105	Atherosclerosis. Current Opinion in Lipidology, 2015, 26, 245-246.	1.2	2
106	Neutrophils in atherosclerosis. Hamostaseologie, 2015, 35, 121-127.	0.9	39
107	Atherosclerotic Plaque Destabilization in Mice: A Comparative Study. PLoS ONE, 2015, 10, e0141019.	1.1	31
108	An inflammatory link in atherosclerosis and obesity. Hamostaseologie, 2015, 35, 272-278.	0.9	12

#	Article	IF	Citations
109	Thymic B Cells Are Licensed to Present Self Antigens for Central T Cell Tolerance Induction. Immunity, 2015, 42, 1048-1061.	6.6	201
110	Discovery of Small Molecule CD40â€“TRAF6 Inhibitors. Journal of Chemical Information and Modeling, 2015, 55, 294-307.	2.5	58
111	Blocking CD40-TRAF6 interactions by small-molecule inhibitor 6860766 ameliorates the complications of diet-induced obesity in mice. International Journal of Obesity, 2015, 39, 782-790.	1.6	49
112	Targeting the adaptive immune system: new strategies in the treatment of atherosclerosis. Expert Review of Clinical Pharmacology, 2015, 8, 297-313.	1.3	13
113	Platelet CD40L Modulates Thrombus Growth Via Phosphatidylinositol 3-Kinase Î², and Not Via CD40 and IÎºB Kinase Î±. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1374-1381.	1.1	31
114	Regulation of atherosclerotic plaque inflammation. Journal of Internal Medicine, 2015, 278, 462-482.	2.7	70
115	Cytokines and Immune Responses in Murine Atherosclerosis. Methods in Molecular Biology, 2015, 1339, 17-40.	0.4	17
116	Salsalate Activates Brown Adipose Tissue in Mice. Diabetes, 2015, 64, 1544-1554.	0.3	38
117	Effects of Exogenous Recombinant APC in Mouse Models of Ischemia Reperfusion Injury and of Atherosclerosis. PLoS ONE, 2014, 9, e101446.	1.1	10
118	CD40-CD40L: a Janus-faced interaction. Thrombosis and Haemostasis, 2014, 112, 223.	1.8	1
119	P478Ablation of CD8+ dendritic cell mediated cross presentation does not impact atherosclerosis in LDLR deficient mice. Cardiovascular Research, 2014, 103, S87.3-S87.	1.8	0
120	Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 2686-2691.	3.3	112
121	Immune Cell Crosstalk in Obesity: A Key Role for Costimulation?. Diabetes, 2014, 63, 3982-3991.	0.3	98
122	Hypercholesterolemiaâ€induced priming of hematopoietic stem and progenitor cells aggravates atherosclerosis. FASEB Journal, 2014, 28, 2202-2213.	0.2	97
123	Dual role of B7 costimulation in obesity-related nonalcoholic steatohepatitis and metabolic dysregulation. Hepatology, 2014, 60, 1196-1210.	3.6	57
124	Atherosclerosis. Current Opinion in Lipidology, 2014, 25, 408-409.	1.2	0
125	Targeting Hdac3 limits foam cell formation and improves atherosclerotic plaque stability. Atherosclerosis, 2014, 235, e16-e17.	0.4	0
126	MiR-92a. Circulation Research, 2014, 114, 399-401.	2.0	16

#	Article	IF	Citations
127	Atherosclerotic Plaque Destabilization. Circulation Research, 2014, 114, 214-226.	2.0	266
128	Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions. EMBO Molecular Medicine, 2014, 6, 1124-1132.	3.3	140
129	Mast Cells Control the Expansion and Differentiation of IL-10â€“Competent B Cells. Journal of Immunology, 2014, 193, 4568-4579.	0.4	33
130	High Expression of C5L2 Correlates with High Proinflammatory Cytokine Expression in Advanced Human Atherosclerotic Plaques. American Journal of Pathology, 2014, 184, 2123-2133.	1.9	26
131	Platelet-derived PF4 reduces neutrophil apoptosis following arterial occlusion. Thrombosis and Haemostasis, 2014, 112, 562-564.	1.8	27
132	Dual role of B7 costimulation in obesity-related non-alcoholic steatohepatitis (NASH) and metabolic dysregulation. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	0.6	2
133	Inflammation and immune system interactions in atherosclerosis. Cellular and Molecular Life Sciences, 2013, 70, 3847-3869.	2.4	241
134	Macrophage MicroRNA-155 Promotes Cardiac Hypertrophy and Failure. Circulation, 2013, 128, 1420-1432.	1.6	225
135	Abrogated transforming growth factor beta receptor II (TGFÎ²RII) signalling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis. European Heart Journal, 2013, 34, 3717-3727.	1.0	62
136	Lymphocytic tumor necrosis factor receptor superfamily co-stimulatory molecules in the pathogenesis of atherosclerosis. Current Opinion in Lipidology, 2013, 24, 518-524.	1.2	17
137	CD40â€“CD40L: Linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications. Diabetes and Vascular Disease Research, 2013, 10, 115-122.	0.9	40
138	Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. EMBO Molecular Medicine, 2013, 5, 471-481.	3.3	169
139	Stabilin-1 mediated monocyte adhesion protects against adverse cardiac inflammation during viral myocarditis. European Heart Journal, 2013, 34, 2788-2788.	1.0	7
140	Inactivation of the immune receptor CD40 attenuates the development of cardiac hypertrophy in angiotensin-II induced hypertensive heart disease. European Heart Journal, 2013, 34, P5701-P5701.	1.0	0
141	Abstract 32: Hypercholesterolemia-induced Priming of Hematopoietic Stem and Progenitor Cells Aggravates Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, .	1.1	0
142	Abstract 14: Small Molecule Inhibitors of the CD40-TRAF6 Interaction Reduce Atherosclerosis by Inducing Hypo-inflammatory Myeloid Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, .	1.1	0
143	Auto-Antigenic Protein-DNA Complexes Stimulate Plasmacytoid Dendritic Cells to Promote Atherosclerosis. Circulation, 2012, 125, 1673-1683.	1.6	347
144	Models and Analysis of Atherosclerosis, Restenosis, and Aneurysm Formation in the Mouse. Current Protocols in Mouse Biology, 2012, 2, 317-345.	1.2	4

#	Article	IF	Citations
145	Thrombospondin-2 prevents cardiac injury and dysfunction in viral myocarditis through the activation of regulatory T-cells. Cardiovascular Research, 2012, 94, 115-124.	1.8	64
146	Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis, 2012, 225, 461-468.	0.4	490
147	RANK(L)-ing biomarkers as surrogates for coronary calcium score. Thrombosis and Haemostasis, 2012, 107, 3-3.	1.8	1
148	Deficient CD40â€“TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response towards an anti-inflammatory profile. Vascular Pharmacology, 2012, 56, 337.	1.0	2
149	Plasmacytoid Dendritic Cells Protect Against Atherosclerosis by Tuning T-Cell Proliferation and Activity. Circulation Research, 2011, 109, 1387-1395.	2.0	115
150	Caveolinâ€1 deficiency decreases atherosclerosis by hampering leukocyte influx into the arterial wall and generating a regulatory Tâ€cell response. FASEB Journal, 2011, 25, 3838-3848.	0.2	40
151	The structure-function relationship of activated protein C. Thrombosis and Haemostasis, 2011, 106, 1034-1045..	1.8	36
152	Immunology of atherosclerosis. Thrombosis and Haemostasis, 2011, 106, 755-756.	1.8	11
153	CD40L Deficiency Ameliorates Adipose Tissue Inflammation and Metabolic Manifestations of Obesity in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2251-2260.	1.1	74
154	Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood, 2010, 115, 2264-2273.	0.6	157
155	Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood, 2010, 116, 4317-4327.	0.6	249
156	CD40L-CD40 fuel ignites obesity. Thrombosis and Haemostasis, 2010, 103, 694-695.	1.8	6
157	The role of CD154 in haematopoietic development. Thrombosis and Haemostasis, 2010, 104, 639-701.	1.8	22
158	Soluble CD40 Ligand Impairs the Function of Peripheral Blood Angiogenic Outgrowth Cells and Increases Neointimal Formation After Arterial Injury. Circulation, 2010, 121, 315-324.	1.6	43
159	Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. Journal of Experimental Medicine, 2010, 207, 391-404.	4.2	232
160	Myeloid Type I Interferon Signaling Promotes Atherosclerosis by Stimulating Macrophage Recruitment to Lesions. Cell Metabolism, 2010, 12, 142-153.	7.2	212
161	W7 DEFICIENT CD40-TRAF6 SIGNALING IN LEUKOCYTES PREVENTS ATHEROSCLEROSIS BY SKEWING THE IMMUNE RESPONSE TOWARDS AN ANTI-INFLAMMATORY PROFILE. Atherosclerosis Supplements, 2010, 11, 2.	1.2	0
162	Cathepsin K gene disruption does not affect murine aneurysm formation. Atherosclerosis, 2010, 209, 96-103.	0.4	23

#	Article	IF	Citations
163	Endothelial Surface Layer Degradation by Chronic Hyaluronidase Infusion Induces Proteinuria in Apolipoprotein E-Deficient Mice. PLoS ONE, 2010, 5, e14262.	1.1	50
164	The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thrombosis and Haemostasis, 2009, 102, 206-214.	1.8	117
165	Regulatory T Cells Modulate Postischemic Neovascularization. Circulation, 2009, 120, 1415-1425.	1.6	82
166	Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital model. Journal of Thrombosis and Haemostasis, 2009, 7, 152-161.	1.9	98
167	The immunobiology of CD154â€“CD40â€“TRAF interactions in atherosclerosis. Seminars in Immunology, 2009, 21, 308-312.	2.7	65
168	Delivery of MicroRNA-126 by Apoptotic Bodies Induces CXCL12-Dependent Vascular Protection. Science Signaling, 2009, 2, ra81.	1.6	1,165
169	Pleiotropic role of growth arrest-specific gene 6 in atherosclerosis. Current Opinion in Lipidology, 2009, 20, 386-392.	1.2	19
170	Absence of p55 TNF Receptor Reduces Atherosclerosis, but Has No Major Effect on Angiotensin II Induced Aneurysms in LDL Receptor Deficient Mice. PLoS ONE, 2009, 4, e6113.	1.1	42
171	Genetic loss of Gas6 induces plaque stability in experimental atherosclerosis. Journal of Pathology, 2008, 216, 55-63.	2.1	54
172	Anti-oxLDL antibody isotype levels, as potential markers for progressive atherosclerosis in APOEâ^'/â^' and APOEâ^'/â^'CD40Lâ^'/â^' mice. Clinical and Experimental Immunology, 2008, 154, 264-269.	1.1	19
173	CD40 Ligand+ Microparticles From Human Atherosclerotic Plaques Stimulate Endothelial Proliferation and Angiogenesis. Journal of the American College of Cardiology, 2008, 52, 1302-1311.	1.2	176
174	The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood, 2008, 111, 4596-4604.	0.6	80
175	Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. Blood, 2008, 111, 4096-4105.	0.6	137
176	Control of atherosclerotic plaque vulnerability: Insights from transgenic mice. Frontiers in Bioscience - Landmark, 2008, Volume, 6289.	3.0	16
177	Disruption of hedgehog signalling in ApoE â^' /â^' mice reduces plasma lipid levels, but increases atherosclerosis due to enhanced lipid uptake by macrophages. Journal of Pathology, 2007, 212, 420-428.	2.1	27
178	CD40 and Its Ligand in Atherosclerosis. Trends in Cardiovascular Medicine, 2007, 17, 118-123.	2.3	104
179	Is there more than C-reactive protein and fibrinogen?. Atherosclerosis, 2006, 187, 18-25.	0.4	73
180	Gene profiling of cathepsin K deficiency in atherogenesis: profibrotic but lipogenic. Journal of Pathology, 2006, 210, 334-343.	2.1	26

#	Article	IF	Citations
181	Liposome-enhanced MRI of neointimal lesions in the ApoE-KO mouse. Magnetic Resonance in Medicine, 2006, 55, 1170-1174.	1.9	57
182	Disruption of the Cathepsin K Gene Reduces Atherosclerosis Progression and Induces Plaque Fibrosis but Accelerates Macrophage Foam Cell Formation. Circulation, 2006, 113, 98-107.	1.6	211
183	Genome-Wide Expression Studies of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1226-1235.	1.1	45
184	Magnetic resonance imaging of atherosclerosis. European Radiology, 2005, 15, 1087-1099.	2.3	54
185	Genetic Deletion or Antibody Blockade of Î±1Î²1 Integrin Induces a Stable Plaque Phenotype in ApoEâ¯/â¯ Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1917-1924.	1.1	30
186	Polycyclic aromatic hydrocarbons induce an inflammatory atherosclerotic plaque phenotype irrespective of their DNA binding properties. FASEB Journal, 2005, 19, 1290-1292.	0.2	89
187	Gene Profiling in Atherosclerosis Reveals a Key Role for Small Inducible Cytokines. Circulation, 2005, 111, 3443-3452.	1.6	100
188	Leukocyte CD40L deficiency affects the CD25+ CD4 T cell population but does not affect atherosclerosis. Atherosclerosis, 2005, 183, 275-282.	0.4	31
189	Loss of Matrix Metalloproteinase-9 or Matrix Metalloproteinase-12 Protects Apolipoprotein Eâ€“Deficient Mice Against Atherosclerotic Media Destruction but Differentially Affects Plaque Growth. Circulation, 2004, 109, 1408-1414.	1.6	273
190	Fibroblast growth factor 2 endocytosis in endothelial cells proceed via syndecan-4-dependent activation of Rac1 and a Cdc42-dependent macropinocytic pathway. Journal of Cell Science, 2004, 117, 3189-3199.	1.2	129
191	HMG-coA reductase inhibitors: lipid-lowering and beyond. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 189-194.	0.5	4
192	Chronic Exposure to the Carcinogenic Compound Benzo[a]Pyrene Induces Larger and Phenotypically Different Atherosclerotic Plaques in ApoE-Knockout Mice. American Journal of Pathology, 2004, 164, 101-108.	1.9	67
193	The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis. Journal of Pathology, 2003, 200, 516-525.	2.1	114
194	Atherosclerotic Plaque Rupture. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 2123-2130.	1.1	146
195	The atherogenic effect of excess methionine intake. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15089-15094.	3.3	147
196	Hypoxia Induces Aortic Hypertrophic Growth, Left Ventricular Dysfunction, and Sympathetic Hyperinnervation of Peripheral Arteries in the Chick Embryo. Circulation, 2002, 105, 2791-2796.	1.6	116
197	Transforming Growth Factor-Î² Mediates Balance Between Inflammation and Fibrosis During Plaque Progression. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 975-982.	1.1	300
198	CD40-CD40L Interactions in Atherosclerosis. Trends in Cardiovascular Medicine, 2002, 12, 27-32.	2.3	154

#	Article	IF	Citations
199	Dynamics of cardiac wound healing following myocardial infarction: observations in genetically altered mice. Acta Physiologica Scandinavica, 2001, 173, 75-82.	2.3	100
200	Differential Expression of Bone Matrix Regulatory Proteins in Human Atherosclerotic Plaques. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1998-2003.	1.1	630
201	Compensatory Enlargement and Stenosis Develop in ApoE ^{â^'/â^'} and ApoE*3-Leiden Transgenic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1359-1365.	1.1	24
202	Transforming Growth Factor-Î². Circulation Research, 2001, 89, 853-855.	2.0	23
203	The APO*E3-Leiden mouse as an animal model for basal laminar deposit. British Journal of Ophthalmology, 2000, 84, 1415-1419.	2.1	66
204	Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 7464-7469.	3.3	241
205	Chronic myocardial infarction in the mouse: cardiac structural and functional change. Cardiovascular Research, 1999, 41, 586-593.	1.8	160
206	Biphasic pattern of cell turnover characterizes the progression from fatty streaks to ruptured human atherosclerotic plaques. Cardiovascular Research, 1999, 41, 473-479.	1.8	160
207	Atherosclerosis in APOE*3-Leiden Transgenic Mice. Circulation, 1999, 99, 276-283.	1.6	95
208	Requirement for CD154 in the progression of atherosclerosis. Nature Medicine, 1999, 5, 1313-1316.	15.2	404
209	Targeted Deficiency or Cytosolic Truncation of the VE-cadherin Gene in Mice Impairs VEGF-Mediated Endothelial Survival and Angiogenesis. Cell, 1999, 98, 147-157.	13.5	1,167
210	Proliferation in Different Stages of Development of Atherosclerotic Lesions in APOE*3-Leiden Mice. Journal of the American College of Cardiology, 1998, 31, 420A-421A.	1.2	0